Canada: Supreme Court Denies Leave In Takeda Canada Inc. v. Minister of Health, Attorney General of Canada

Last Updated: June 19 2013
Article by Adam Bobker and Matthew Cahill (Summer Student)

The Supreme Court of Canada denied leave to appeal today from the Federal Court of Appeal (the "FCA") decision in Takeda Canada Inc. v. Minister of Health, Attorney General of Canada, 2013 FCA 13. This proceeding arises from the Minister's refusal to list Takeda's drug, DEXILANT, on the Register of Innovative Drugs and provide data protection in accordance with section C.08.004.1 of the Food and Drug Regulations, CRC c 870, as amended by the Regulations Amending the Food and Drug Regulations (Data Protection), SOR/2006-241.

The data protection regulations were enacted to comply with Canada's obligations under Article 1711 of the North American Free Trade Agreement, 1992, 32 ILM 296 ("NAFTA") and paragraph 3 of Article 39 in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 1869 UNTS 299 ("TRIPS"). These agreements require that "...where a person submits undisclosed data for approval of a pharmaceutical product, and the product utilizes a 'new chemical entity', signatory states commit to preventing other persons from making 'unfair commercial use' of that data and (for a reasonable time) from relying on that data in their own applications for approval" (2011 FC 1444, at 13).

The protection granted to innovative drugs under the Canadian data protection regulations takes two forms. "Firstly, a generic drug manufacturer cannot file a submission based on a comparison to an 'innovative drug' within the first six years of the eight-year period after the drug has received a Notice of Compliance ("NOC") (subsection C.08.004.01(3)(a)). Secondly, the Minister may not issue a NOC to the generic drug manufacturer before the end of the eight-year period (subsection C.08.004.01 (3)(b))" (2011 FC 1444, at 12).

DEXILANT is a trade name for dexlansoprazole, a compound intended for use in the treatment of, among other things, gastroesophageal reflux disease ("GERD"). Dexlansoprazole is an enantiomer of lansoprazole. A racemic mixture of the two lansoprazole enantiomers, dexlansoprazole and levlansoprazole, is currently marketed by Takeda as the drug PREVACID, also used for the treatment GERD.

In August of 2009, Takeda Canada Inc. filed a New Drug Submission for DEXILANT. A NOC to market the drug was issued in July 22, 2010. However, the Office of the Patented Medicines and Liaison ("OPML") decided, on behalf of the Minister, that DEXILANT did not meet the definition of "innovative drug" as required by the regulations. The OPML took the position that because dexlansoprazole was an enantiomer of the previously-approved medicinal ingredient lansoprazole, it was a "variation" within the meaning of the Regulations and therefore not eligible for data protection. Takeda applied to the Federal Court (FC) for judicial review of this decision.

The Federal Court dismissed the application for judicial review (2011 FC 1444). Data protection under section C.08.004.1 of the Food and Drug Regulations (the "Regulations") is extended to "innovative drugs". The issue before the Federal Court was whether the Minister erred in interpreting section C.08.004.1(1) of the Food and Drug Regulations which defines an innovative drug as a "drug that contains a medicinal ingredient not previously approved in a drug by the Minister and that is not a variation of a previously approved medicinal ingredient such as a salt, ester, enantiomer, solvate or polymorph." Justice Near held that the Minister was correct in interpreting the regulation to mean that, as an enantiomer of a previously approved medicinal ingredient, dexlansoprazole was not entitled to data protection. This decision was appealed.

The Majority of the FCA upheld the decision of the Federal Court and endorsed the Minister's interpretation of "innovative drug" (2013 FCA 13). The FCA held that the ordinary wording of the Regulations excludes all enantiomers of previously approved medicinal ingredients from qualifying as "innovative drugs".

Writing for the Majority, Justice Dawson noted that Canada's obligations under NAFTA and TRIPS required that the Governor in Council consider what constitutes "new chemical entities" when crafting the data protection regulations. However, it "...was open to the Governor in Council to decide, as a matter of policy, that salts, esters, enantiomers, solvates and polymorphs were not sufficiently different to be "new chemical entities" and that the Court "...ought not to thwart the decision of the Governor in Council as expressed in the definition of 'innovative drug'" (2013 FCA 13, at 131).

Dissenting, Justice Stratas held that the listed categories in the definition of innovative drugs are examples of substances that may be "variations". In his view, a drug should not be automatically excluded from protection solely on the basis that it contains an ingredient that is an enantiomer of a previously approved medicinal ingredient. Under Justice Stratas' interpretation, the data protection regulations extend to medicinal ingredients that have "safety and efficacy characteristics materially different from a previously approved medicinal ingredient" (2013 FCA 13, at 102). That such an ingredient might be an enantiomer would not be determinative. Justice Stratas would have quashed the Minister's decision and remitted the matter to the Minister for redetermination in light of his interpretation of the Regulations.

The decision in this case, and the recent decision in Canada (Health) v. Celgene Inc. ( summary), indicates that Canadian courts are taking a strict approach to the definition of "innovative drug".

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Adam Bobker
Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions